FI108138B - Förfarande för framställning av terapeutiskt användbara 3,4[(N,N'-1,1')-substituerad alkylen)-bis(3,3'-indolyl)]1H-pyrrol-2,5-dionderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara 3,4[(N,N'-1,1')-substituerad alkylen)-bis(3,3'-indolyl)]1H-pyrrol-2,5-dionderivat Download PDF

Info

Publication number
FI108138B
FI108138B FI945706A FI945706A FI108138B FI 108138 B FI108138 B FI 108138B FI 945706 A FI945706 A FI 945706A FI 945706 A FI945706 A FI 945706A FI 108138 B FI108138 B FI 108138B
Authority
FI
Finland
Prior art keywords
mmol
bis
indolyl
dione
pyrrole
Prior art date
Application number
FI945706A
Other languages
English (en)
Finnish (fi)
Other versions
FI945706A0 (sv
FI945706A (sv
Inventor
Michael Robert Jirousek
Iii John Hampton Mcdonald
Christopher John Rito
Jr William Francis Heath
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI945706A0 publication Critical patent/FI945706A0/sv
Publication of FI945706A publication Critical patent/FI945706A/sv
Application granted granted Critical
Publication of FI108138B publication Critical patent/FI108138B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/17—Unsaturated ethers containing halogen
    • C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
    • C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Claims (4)

1. Förfarande för framställning av nya ‘ terapeutiskt användbara 3,4-[(N,Ν'-1,1')- (substituerad 5 alkylen)-bis(3,3'-indolyl)]-lH-pyrrol-2,5-dionderivat med formeln 1' H (i,> I I 15 (CH2) 2 <CH2)2 väri W är -0-, -CH2-0-CH(R' )-0-CH(Rf)-, 20 -0-CH2-CH (R' ) -, - (CH2) n-, -CH2-CH (R' ) -, -CH2-CH (R' ) -CH2-, -CH2-S-CH2-, -CH(R')-, -CH2-CH(R*')-CH2- eller -CH2-C(=R''')-CH2-, varvid n är ett heltal 1-4, R' är en grupp med formeln -CH2-R, varvid R är 25 -OH, -NH2, -NHCH3, -N (CH3) 2, -NHCH2Ph, -N(CH2Ph)2, -NHC0CH3, -NHC (0) 0CH2Ph, -NHS02Ph, -N [- (CH2) 4-] , -N [ - (CH2) 2-N (C1-4-alkyl) - (CH2) 2-] , -N [-(CH2) 2-0- (CH2) 2-] , -pyrrolyl, -imidazo-lyl, -OCH3, -OCOOCH2Ph, -OCH2Ph, -OCOCH3 eller -0S02CH3, R' ' är -NH2, -NHCH2Ph eller -NHCOCH3 ooh 30 R''' är -0CH2CH20- eller =0, samt farmaceutiskt godtagbara salter därav, kännetecknat därav, att en förening med formeln II' ^08738 116 ογ°γ° 5 n I I (CH2)2 (ch2)2 "-(W)" väri W betecknar sarana som ovan, överförs genom 10 ammonolysering med hexametyldisilazan till motsvarande förening med formeln I'.
2. Förfarande enligt patentkrav 1, känne-tecknat därav, att man framställer 3,4-[(N,N'-1,1') -((2' '-etoxi)-3'' '(0)-4'''-(N,N-dimetylamino)butan)- 15 bis(3,3'-indolyl)]-1(H)-pyrrol-2,5-dion.
3. Förfarande enligt patentkrav 1, känneteck- nat därav, att man framställer 3,4-[ (N, N'-1, 1') - ( (2'' - etoxi)-3''' (0) -4' ' ' -(N-pyrrolidin)butan)-bis(3,3'-indolyl) ]-1(H)-pyrrol-2,5-dion. 20
4 . Förfarande enligt patentkrav 1, känneteck- nat därav, att man framställer 3,4-[(N,N'-l,l')-((2''- etoxi)-3''' (0)-4 ' ' ' - (N-fenylsulfonamido) butan)-bis(3,3' -indolyl)]-1(H)-pyrrol-2,5-dion.
FI945706A 1993-12-07 1994-12-02 Förfarande för framställning av terapeutiskt användbara 3,4[(N,N'-1,1')-substituerad alkylen)-bis(3,3'-indolyl)]1H-pyrrol-2,5-dionderivat FI108138B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16306093A 1993-12-07 1993-12-07
US16306093 1993-12-07
US31697394A 1994-10-03 1994-10-03
US31697394 1994-10-03

Publications (3)

Publication Number Publication Date
FI945706A0 FI945706A0 (sv) 1994-12-02
FI945706A FI945706A (sv) 1995-06-08
FI108138B true FI108138B (sv) 2001-11-30

Family

ID=26859318

Family Applications (3)

Application Number Title Priority Date Filing Date
FI945706A FI108138B (sv) 1993-12-07 1994-12-02 Förfarande för framställning av terapeutiskt användbara 3,4[(N,N'-1,1')-substituerad alkylen)-bis(3,3'-indolyl)]1H-pyrrol-2,5-dionderivat
FI20000516A FI20000516A (sv) 1993-12-07 2000-03-07 Bis-indolylmaleimidderivat samt deras framställning
FI20011109A FI20011109A (sv) 1993-12-07 2001-05-28 Bis-indolylsuccinimidderivat samt deras framställning

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI20000516A FI20000516A (sv) 1993-12-07 2000-03-07 Bis-indolylmaleimidderivat samt deras framställning
FI20011109A FI20011109A (sv) 1993-12-07 2001-05-28 Bis-indolylsuccinimidderivat samt deras framställning

Country Status (31)

Country Link
US (1) US5698578A (sv)
EP (1) EP0657458B1 (sv)
JP (2) JP3581731B2 (sv)
KR (1) KR100340159B1 (sv)
CN (2) CN1050844C (sv)
AT (1) ATE204579T1 (sv)
AU (1) AU687909B2 (sv)
BR (1) BR9404831A (sv)
CA (1) CA2137203C (sv)
CO (1) CO4340622A1 (sv)
CY (1) CY2413B1 (sv)
CZ (1) CZ291950B6 (sv)
DE (1) DE69428025T2 (sv)
DK (1) DK0657458T3 (sv)
ES (1) ES2162843T3 (sv)
FI (3) FI108138B (sv)
GR (1) GR3037087T3 (sv)
HK (1) HK1013827A1 (sv)
HU (1) HU219709B (sv)
IL (1) IL111850A (sv)
MY (1) MY125587A (sv)
NO (1) NO308798B1 (sv)
NZ (1) NZ270048A (sv)
PE (1) PE49195A1 (sv)
PL (1) PL182124B1 (sv)
PT (1) PT657458E (sv)
RU (1) RU2147304C1 (sv)
SG (1) SG63570A1 (sv)
TW (1) TW425397B (sv)
UA (1) UA44690C2 (sv)
YU (1) YU49200B (sv)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
HU226821B1 (en) * 1995-11-20 2009-11-30 Lilly Co Eli The mesylate salt of a macrocyclic bis-indolyl-maleimide derivative, process for its preparation, use thereof and pharmaceutical compositions containing the same
TW371661B (en) 1995-11-20 1999-10-11 Lilly Co Eli Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
CA2249205A1 (en) * 1996-03-20 1997-09-25 Eli Lilly And Company Synthesis of indolylmaleimides
PL329851A1 (en) * 1996-05-01 1999-04-12 Lilly Co Eli Treatment of diseases associated with vegf
KR20000065137A (ko) * 1996-05-01 2000-11-06 미시시피 스테이트 유니버시티 할로-치환된 단백질 키나제 c 억제제
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
EA199900244A1 (ru) * 1996-08-30 1999-10-28 Эли Лилли Энд Компани Применение ингибиторов протеинкиназы с для производства лекарственных препаратов для лечения заболеваний центральной нервной системы, связанных с вич инфекцией
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
AU4250697A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
US5721272A (en) * 1996-11-18 1998-02-24 Eli Lilly And Company Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
JPH1135454A (ja) * 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd 抗腫瘍剤
US6620977B1 (en) 1998-01-30 2003-09-16 Daiso Co., Ltd. Process for producing butanetriol derivative
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
EP1070068B2 (en) * 1998-03-13 2007-01-17 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
MXPA03005139A (es) 2000-12-08 2004-01-29 Ortho Mcneil Pharm Inc Compuestos macroheterociclicos utiles como inhibidores de cinasa.
DE10109280A1 (de) * 2001-02-26 2002-09-05 Peter Mayser Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen
US20030119812A1 (en) * 2001-11-08 2003-06-26 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
WO2003059372A2 (en) * 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
US6887864B2 (en) 2002-03-12 2005-05-03 Hoffmann-La Roche Inc. Azepane derivatives
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10233737A1 (de) * 2002-07-24 2004-02-05 Morphochem Aktiengesellschaft für kombinatorische Chemie Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
BRPI0413439A (pt) 2003-08-08 2006-10-17 Novartis Ag combinações compreendendo estaurosporinas
AU2005221283C1 (en) * 2004-03-17 2011-02-03 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
EP1998776A4 (en) * 2006-03-10 2009-07-08 Janssen Pharmaceutica Nv MACRO-HETEROCYL COMPOUNDS CONTAINING PYRIDINE AS KINASE INHIBITORS
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
RU2012146083A (ru) 2010-03-30 2014-05-10 Новартис Аг Ингибиторы ркс для лечения в-клеточной лимфомы с хроническими активным сигнальным каскадом в-клеточного рецептора
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
HUE037618T2 (hu) 2012-11-29 2018-09-28 Novartis Ag Gyógyszerészeti kombinációk
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
EP3180003B1 (en) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
AU2016296878B2 (en) * 2015-07-21 2020-12-17 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CN106854141A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4-氯甲苯化合物的合成方法
CN107778148A (zh) * 2016-08-30 2018-03-09 湖南华腾制药有限公司 一种溴化苄衍生物的合成方法
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
AU2018306328B2 (en) 2017-07-28 2023-03-09 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN111511746B (zh) 2017-12-19 2024-01-09 特普医药公司 用于治疗疾病的巨环化合物
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
US20230203017A1 (en) * 2021-12-28 2023-06-29 Kamal D. Mehta Protein Kinase C Beta Inhibitors and Uses Thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
EP0303697B1 (en) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
IL94274A0 (en) * 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
EP0580812A1 (en) * 1991-04-11 1994-02-02 Schering Corporation Anti-tumor and anti-psoriatic agents
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
NO944643L (no) 1995-06-08
PL182124B1 (pl) 2001-11-30
FI20011109A (sv) 2001-05-28
DK0657458T3 (da) 2001-10-29
DE69428025T2 (de) 2002-05-29
ES2162843T3 (es) 2002-01-16
NO308798B1 (no) 2000-10-30
DE69428025D1 (de) 2001-09-27
MY125587A (en) 2006-08-30
CN1055089C (zh) 2000-08-02
BR9404831A (pt) 1995-08-08
IL111850A (en) 2002-11-10
PT657458E (pt) 2002-02-28
HU9403468D0 (en) 1995-02-28
UA44690C2 (uk) 2002-03-15
EP0657458A1 (en) 1995-06-14
TW425397B (en) 2001-03-11
AU687909B2 (en) 1998-03-05
JP2004269543A (ja) 2004-09-30
NZ270048A (en) 1996-11-26
ATE204579T1 (de) 2001-09-15
IL111850A0 (en) 1995-03-15
SG63570A1 (en) 1999-03-30
KR100340159B1 (ko) 2002-11-23
NO944643D0 (no) 1994-12-02
HUT71130A (en) 1995-11-28
CN1220266A (zh) 1999-06-23
RU2147304C1 (ru) 2000-04-10
RU94042922A (ru) 1996-12-27
FI20000516A (sv) 2000-03-07
CZ301894A3 (en) 1995-06-14
EP0657458B1 (en) 2001-08-22
YU49200B (sh) 2004-09-03
JP3581731B2 (ja) 2004-10-27
CO4340622A1 (es) 1996-07-30
CA2137203C (en) 2006-11-28
KR950018010A (ko) 1995-07-22
CY2413B1 (en) 2004-11-12
PE49195A1 (es) 1996-01-06
PL306084A1 (en) 1995-06-12
JPH07215977A (ja) 1995-08-15
AU7918894A (en) 1995-06-15
FI945706A0 (sv) 1994-12-02
HK1013827A1 (en) 1999-09-10
FI945706A (sv) 1995-06-08
HU219709B (hu) 2001-06-28
GR3037087T3 (en) 2002-01-31
CA2137203A1 (en) 1995-06-08
YU70494A (sh) 1997-03-07
CN1111247A (zh) 1995-11-08
CZ291950B6 (cs) 2003-06-18
US5698578A (en) 1997-12-16
CN1050844C (zh) 2000-03-29

Similar Documents

Publication Publication Date Title
FI108138B (sv) Förfarande för framställning av terapeutiskt användbara 3,4[(N,N&#39;-1,1&#39;)-substituerad alkylen)-bis(3,3&#39;-indolyl)]1H-pyrrol-2,5-dionderivat
US5621098A (en) Process for preparing bis-indolyl macrocycles
CA2252701C (en) Halo-substituted protein kinase c inhibitors
US5843935A (en) Protein kinase C inhibitors
MXPA98009014A (en) Inhibitors of protein cinasa c, halo-sustitui
IL122092A (en) Cyclic 3, 4-bis (3-indolyl) maleic anhydride and 3, 4-bis (3-indolyl) maleimide intermediates for protein kinase c inhibitors

Legal Events

Date Code Title Description
MA Patent expired